| Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 20924633 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. METHODS: Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10(9)/L) and/or neutropenia (<0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. RESULTS: No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. CONCLUSION: We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy. |
| | |
Authors:
|
Yoshihiro Yakushijin; Hisaharu Shikata; Ikue Takaoka; Tamami Horikawa; Kazuhito Takeuchi; Jun Yamanouchi; Taichi Azuma; Hiroshi Narumi; Takaaki Hato; Masaki Yasukawa |
Related Documents
:
|
19407573 - Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance... 14696433 - Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy wit... 23623403 - Recurrent well-differentiated thyroid carcinoma. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial Date: 2010-10-06 |
Journal Detail:
|
Title: International journal of clinical oncology Volume: 16 ISSN: 1437-7772 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-07 Completed Date: 2011-07-28 Revised Date: 2012-12-13 |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: Japan |
Other Details:
|
Languages: eng Pagination: 118-24 Citation Subset: IM |
Affiliation:
|
Cancer Center of Ehime University Hospital, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 7910295, Japan. yoshiyak@m.ehime-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antibiotics, Antineoplastic / therapeutic use Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects*, therapeutic use Cost-Benefit Analysis Cyclophosphamide / administration & dosage, adverse effects Doxorubicin / administration & dosage, adverse effects Drug Administration Schedule Female Fever / blood, drug therapy* Granulocyte Colony-Stimulating Factor / administration & dosage*, economics Humans Leukocytes / drug effects Lymphoma, Large B-Cell, Diffuse / blood, drug therapy, economics Male Middle Aged Neutropenia / blood, drug therapy*, economics Neutrophils / drug effects Prednisone / administration & dosage, adverse effects Recombinant Proteins / administration & dosage, economics Vincristine / administration & dosage, adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Recombinant Proteins; 135968-09-1/lenograstim; 143011-72-7/Granulocyte Colony-Stimulating Factor; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Myotonic dystrophies as a brain disorder.
Next Document: Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology.